Italia markets closed

BioRestorative Therapies, Inc. (BRTX)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,2500+0,0200 (+1,63%)
Alla chiusura: 04:00PM EDT
1,2200 -0,03 (-2,40%)
Dopo ore: 07:19PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,2300
Aperto1,2300
Denaro1,2300 x 200
Lettera1,2800 x 200
Min-Max giorno1,2400 - 1,3000
Intervallo di 52 settimane1,2000 - 7,1300
Volume57.563
Media Volume668.169
Capitalizzazione8,462M
Beta (5 anni mensile)61,68
Rapporto PE (ttm)N/D
EPS (ttm)-3,4200
Prossima data utili12 mag 2024 - 16 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A10,50
  • GlobeNewswire

    BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

    MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference. Company BioRestorative Therapies, Inc.Presenter Lance Alstodt, Chief Executive OfficerDate & Time Thursday October 12th, 9:00am estLocation Yale Club, 50 Vanderbilt Avenue, NYC

  • GlobeNewswire

    BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

    --BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement --Agreement Represents Initial Venture into the $62.8 Billion Global Aesthetics Market --Initial Order of 5,000 Vials of Product Represents Controlled Launch and Will Have Positive Financial Impact MELVILLE, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a cl

  • GlobeNewswire

    BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

    --Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New York State's largest health care provider, has been activated and can